NASDAQ · CARA
Healthcare · Biotechnology
$5.32
Down-$0.14 (-2.56%)
Updated Sep 16, 2026, 8:36 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CARA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CARA.
CARA research
Company profile and research snapshot.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 13, 2024 | Canaccord Genuity | Hold | — |
| Jun 13, 2024 | HC Wainwright & Co. | Neutral | — |
| Jun 13, 2024 | Needham | Hold | — |
| May 23, 2024 | Needham | Buy | — |
| May 15, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Apr 15, 2025
Tvardi Therapeutics, a clinical-stage biopharmaceutical company, has completed its merger with Cara Therapeutics. The combined company will focus on developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.
Benzinga · Jun 13, 2024
Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points. The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst Joseph Stringer downgraded the rating on the stock from Buy to Hold. HC Wainwright analyst Oren Livnat downgraded the rating on the stock from Buy to Neutral. Check out other analyst stock ratings. Needham: Cara Therapeuticssaidafter market close on Wednesday that "the dose-finding Part A portion of the Ph2/3 KOURAGE trial evaluating oral Korsuva (difelikefalin) in Notalgia Parasthetica (NP) failed to show efficacy vs. pbo," Stringer ...Full story available on Benzinga.com
Benzinga · Jun 13, 2024
Cara Therapeutics (NASDAQ:CARA) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 0 0 0 0 0 1M Ago 3 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.72, a high estimate of $5.00, and a low estimate of $3.60. This current average has increased by 4.19% from the previous average price target of $4.53. Exploring Analyst Ratings: An In-Depth Overview The perception of Cara Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $5.00 $5.00 Oren Livnat HC Wainwright & Co. Maintains Buy $3.60 $3.60 Joseph Stringer Needham Maintains Buy $5.00 $5.00 Joseph Stringer Needham Maintains Buy $5.00 - Joseph Stringer Needham Maintains Buy $5.00 - Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cara Therapeutics. This information provides a snapshot of how analysts perceive ...Full story available on Benzinga.com
GlobeNewswire Inc. · Jun 12, 2024
– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo –
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CARA.
No results
No recent SID articles mention CARA.
